Research

SPP-ARC aims to establish research capabilities that enable rapid responses to emerging pathogens. We focus on workflows to assess and develop antiviral drugs and vaccines. These workflows will be applied in outbreak situations to provide evidence-based recommendations on promising medical countermeasures.

Image of an arrow labelled emerging pathogens. The arrow connects to a cog labelled samples. The sample cog is being moved by another cog labelled virology. The virology cog is moved by 2 cogs labelled vaccines and antivirals respectively. The last cogs connect to another arrow labelled support clinical trials.

Rapid responses rely on the availability of samples and reagents, the development of assays in the broader area of virology, and the evaluation of antivirals and vaccines against the viral threat. These workflows have to be established with known pathogens that represent families of viruses with a high epidemic or pandemic potential. SPP-ARC research is focused on respiratory viruses.